Pharmaceuticals, Biotechnology and Life Sciences
Pfizer is moving forward with Ibrance breast cancer drug as the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA).
Janssen Biotech has submitted two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval…
Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule…
Hansa Medical AB has announced completion of a Phase II study entitled “A Phase II Study to Evaluate the Safety,…
Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from…
Kiadis Pharma has announced an update on the second dose Phase II trial with ATIR101 (CR-AIR-008 ).
Galapagos has reported topline results from its Saphira 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…
Exelixis and Ipsen have signed an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development…
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…